Personalized combination treatment including cognitive behavioural therapy in chronic migraine and depression: A prospective randomized trial
Abstract
Imtroduction. Personalized combination treatment including cognitive behavioural therapy (CBT) is a promising approach for managing chronic migraine (CM) and comorbid depressive syndrome.Aim. To evaluate the effectiveness of adding CBT to personalized combination treatment for patients with CM and comorbid depressive syndrome.Materials and methods. A total of 190 patients with CM and depressive syndrome (59 men and 131 women) were enrolled in the study. The mean age of patients was 35.8 ± 7.6 years. All patients underwent clinical interviews, neurological examination and testing. Patients were randomized into two groups: Group 1 received combination treatment, including pharmacological management of migraine, lifestyle recommendations, detoxification therapy (in the presence of drug-induced headache), therapeutic gymnastics (in the presence of musculoskeletal pain in other locations), sleep hygiene (in the presence of insomnia) and CBT, Group 2 received the same treatment, but without CBT. All patients had their clinical and psychological parameters assessed before treatment and at 3rd, 6th, 12th and 18th months of observation.Results. At Month 3 of treatment, Groups 1 and 2 showed statistically significant (p < 0.05) improvements: decreased frequency of headache (HF), analgesics use, migraine impact on daily activities, as well as reduced anxiety and depression. At Month 3 of treatment, in Group 1 the clinical effect (CE) for CM (a ≥50% reduction in HA frequency) was…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 190 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.